Questions? Feedback? powered by Olark live chat software
All Site

screeningIn Vitro Technologies provides a complete Cardiotoxicity & Drug Discovery platform using the label-free, real-time cell analysis technologies from Agilent and ACEA Biosciences.

Between 1990 and 2006 one third of all safety-related drug withdrawals were due to cardiotoxicity, and cardiac liability continues to be a major hurdle in drug development. There are ongoing efforts to develop higher throughput and more predictive assays that can be used earlier in the drug discovery/development pipeline to minimize both cost and risk. 

  • xCELLigence SP & MP RTCA
  • xCELLigence Cardio & CardioECR RTCA
  • TocriScreen compound libraries
  • Seahorse XF analyzer

Learn more about our range by clicking on the buttons below

t luminex

t realtime

t compound libraries

t high throughput

t cell meta

Our Cardiotoxicity & Drug Discovery Brands





randd logo